FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer By Ogkologos - December 17, 2024 385 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the HERIZON-BTC-01 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence MOST POPULAR Struggling Waitress Who Can’t Feed Her 4 Kids After Husband’s Cancer... May 7, 2019 Maximizing the Prospects for Progress Against Cancer June 11, 2018 ESMO Calls for Cancer to Be at the Core of the... June 10, 2025 Hable con su médico sobre las opciones de cirugía de mama February 13, 2024 Load more HOT NEWS Increased Efficacy of Pembrolizumab or Pembrolizumab-Chemotherapy with Increasing PD-L1 Expression in... Cancer Research UK appoints new Trustees and independent Committee Members Findings support de-escalated radiotherapy after surgery in HPV-associated oropharyngeal squamous cell... Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated...
